Schering-Plough Gains Topical Antifungal In Deal With Anacor
This article was originally published in The Pink Sheet Daily
Executive Summary
Commercialization deal for the nail infection treatment is worth over $600 million for Palo Alto, Calif.-based Anacor.
You may also be interested in...
Anacor’s Topical Psoriasis Candidate Produces Strong Showing In Phase II
Boron-based anti-inflammatory drug targets TNF-a, other cytokine receptors.
Anacor’s Topical Psoriasis Candidate Produces Strong Showing In Phase II
Boron-based anti-inflammatory drug targets TNF-a, other cytokine receptors.
GlaxoSmithKline Invests In Anacor’s Boron-Based Anti-Infectives
Discovery and development deal gives Anacor $12 million upfront, with potential to earn more than $2 billion in milestones for eight possible products.